Epilepsy is a common neurological disorder whose prevalence is 5-8 in every 1,000 individuals, with a cumulative lifetime incidence of 3%. The underlying causes are multiple and heterogeneous. Some of these forms of epilepsy will have an identifiable genetic cause and more and more genes are known responsible for some of these forms of epilepsy, previously labeled as ‘idiopathic’.
Epilepsy is a common neurological disorder whose prevalence is 5-8 in every 1,000 individuals, with a cumulative lifetime incidence of 3%. The underlying causes are multiple and heterogeneous. Some of these forms of epilepsy will have an identifiable genetic cause and more and more genes are known responsible for some of these forms of epilepsy, previously labeled as ‘idiopathic’.
Traditionally, genetic studies in epilepsy have been relegated to complex or refractory patients. However, there are many cost-effective benefits to considering requesting a genetic test within the first tests in a patient who presents with a form of epilepsy. On the other hand, increasingly, studies in epilepsy do not only seek a diagnosis but also an approach to individualized medicine in which the finding of a variant in a certain gene can also provide very valuable help when selecting the best therapeutic strategy.
The clinical manifestations of the different forms of epilepsy will provide very valuable information when deciding to request a genetic study since certain epileptic syndromes will guide the selection of the most appropriate study. To this end, we have designed an offer of panels that attempt to collect the most common causes of epilepsy from a genetic point of view, classified based on the epileptic phenotype to carry out a directed diagnostic genetic study and maintaining a panel general for more imprecise semiological classifications or more complex cases where it is necessary to cover a broad differential diagnosis.
Various studies carried out on the diagnostic performance of genetic panels for epilepsy place a diagnostic rate of around 15-25%. Of course, this performance varies depending on selection of patients, their clinical indication, age, and the presence of family history. It is likely that we still do not know many of the genes involved in epilepsy, although it is worth remembering that since it is such a common and heterogeneous disease, it is necessary to place it in its multifactorial context. Studies aimed at more selected patients have achieved diagnostic rates of up to 60-70% in early-onset epileptic encephalopathies, for example.
How to order
1. Download & fill out
Please cover as many fields as possible in both documents
2. Sample collection
Three sample types: saliva, peripheral blood or genomic DNA
3. Pack the sample
Please pack the sample in a way to prevent leakage
4. Send the sample & the request
Please schedule the delivery for Monday–Friday: 8am – 5pm
5. Result: the report
Via: e-mail and/or through the customer portal
"*" indicates required fields
Turnaround time (TAT): 25 days
Ref. S-202008564
Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.
